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Abstract: HER2 positive JIMT-1 breast tumors are resistant to trastuzumab treatment in vitro and 
develop resistance to trastuzumab in vivo in SCID mice. We explored whether these resistant 
tumors could still be eliminated by T cells redirected by a second-generation chimeric antigen 
receptor (CAR) containing a CD28 costimulatory domain and targeting HER2 with a trastuzumab-
derived scFv. In vitro, T cells engineered with this HER2 specific CAR recognized HER2 positive 
target cells as judged by cytokine production and cytolytic activity. In vivo, the administration of 
trastuzumab twice weekly had no effect on the growth of JIMT-1 xenografts in SCID mice. At the 
same time, a single dose of 2.5 million T cells from congenic mice exhibited a moderate xenoimmune 
response and even stable disease in some cases. In contrast, when the same dose contained 7% 
(175,000) CAR T cells, complete remission was achieved in 57 days. Even a reduced dose of 250,000 
T cells, including only 17,500 CAR T cells, yielded complete remission, although it needed nearly 
twice the time. We conclude that even a small number of CAR T lymphocytes can evoke a robust 
anti-tumor response against an antibody resistant xenograft by focusing the activity of xenogenic T 
cells. This observation may have significance for optimizing the dose of CAR T cells in the therapy 
of solid tumors.  
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1. Introduction 
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20–25% of breast cancer 
tumors [1]. HER2 expression is associated with an aggressive disease with a high recurrence rate and 
increased mortality [2]. Specific monoclonal antibody therapy has revolutionized the treatment of 
HER2 positive breast cancer since the FDA (U.S. Food and Drug Administration) approval of 
trastuzumab (Herceptin®) in 1998 [3]. The addition of trastuzumab to chemotherapy results in a lower 
rate of death after one year (22 percent vs. 33 percent, P = 0.008), longer survival (median survival, 
25.1 vs. 20.3 months; P=0.046), and a 20 percent reduction in the risk of death [4]. Despite the success, 
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resistance to therapeutic antibodies is a clinical reality that affects the outcome of 60–80% of HER2+ 
breast cancer patients [5]. One of the underlying mechanisms is epitope masking by components of 
the tumor microenvironment (TME) such as the MUC4 (mucin 4) or the CD44/Hyaluronan complex 
[6–11]. 
The JIMT-1 cell line was established from the pleural metastasis of a breast cancer patient and 
has recapitulated the trastuzumab resistance of the original tumor in vitro and also in vivo if 
treatment of JIMT-1 xenografts SCID mice was initiated at a few hundred mm3 tumor volumes [12–
14]. Our recent data indicate that simultaneous targeting of two epitopes on the HER2 molecule with 
clinical doses of trastuzumab and pertuzumab additionally improves the efficacy of antibody-
dependent cellular cytotoxicity and thereby also the anti-tumor response; however, eventually all 
JIMT-1 xenografts become resistant to antibody treatment at a certain tumor size [15]. 
In such cases of antibody resistance, Chimeric Antigen Receptor (CAR) engineered T cells [16] 
represent an appealing option for improving the outcome for patients with advanced breast cancer 
[17–20]. Several tumor-associated membrane proteins are targeted in clinical trials by CAR T cells, 
including HER2 (NCT02547961, NCT02713984), CEA (NCT02349724) and mesothelin 
(NCT02792114). While no results have been disclosed of current HER2 targeting trials, the first 
reported clinical use of HER2 specific CAR T cells resulted in a serious adverse event following CAR 
T cell infusion [21]. In this trial, a HER2 positive colon cancer patient was treated with a large number 
(1010) of CD28-41BB costimulatory (3rd-generation) CAR T cells, which derived their antigen 
specificity from trastuzumab. The patient developed respiratory distress, followed by multiple 
cardiac arrests over the course of 5 days, leading to death. The death of this patient may have occurred 
due to the result of HER2 recognition of highly active and numerous anti-HER2 CAR T cells in the 
normal lung tissue that caused pulmonary toxicity and edema followed by a cytokine release storm 
causing multiorgan failure. The immune-mediated recognition of tumor antigens in normal tissues 
is referred to as “on-target, off-tumor” toxicity. It is thus clear from both preclinical experiments and 
clinical trials that while CAR T cell-based immune therapy has great potential to improve the 
outcome for patients with HER2 positive tumors, it still needs plentiful optimization. 
Here, we report the generation of mouse T cells that are genetically modified to express a 
chimeric antigen receptor that consists of a HER2 specific single-chain variable fragment (scFv) 
derived from trastuzumab, a CD28 costimulatory endodomain, and a CD3z intracellular signaling 
domain. We demonstrate that these T cells recognize and kill HER2+ tumor cells in vitro and 
significantly improve the xenogenic immune response against human breast cancer even at very low 
numbers (17,500), resulting in complete tumor regression, and significant survival advantage.  
2. Results 
2.1. Generation of Murine HER2 Specific CAR T Cells 
To genetically modify mouse T cells (Figure 1), first, we generated VSVG-pseudotyped retroviral 
particles encoding HER2 specific chimeric antigen receptors (Figure 1A). T cells were isolated from 
the freshly dissected spleen of congenic Balb/c mice and activated by anti-mouse CD3e and anti-
mouse CD28 antibodies. After 24 h, the medium was supplemented with mouse interleukin 2. Finally, 
activated mouse T cells were retrovirally transduced on RetroNectin-coated plates (Figure 1B). 
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Figure 1. Genetic modification of mouse T cells with chimeric antigen receptors: (A) Scheme of 
retrovirus production. (B) Scheme of mouse T cell separation and activation. 
The CAR contains an scFv obtained from trastuzumab, an IgG1 CH2-CH3 extracellular stalk, a 
CD28 costimulatory endodomain and a CD3z effector domain (Figure 2A). Using trastuzumab as a 
recognition domain allowed us to compare the impact of CAR T cells as living drugs with the impact 
of antibodies. The mean transduction efficiency was 8.7% (range: 5.58–11.84%; n = 8) as judged by 
flow cytometric analysis of the HER2 specific scFv (Figure 2B,C). We confirmed that CARs are stably 
expressed and re-confirmed CAR expression on day 10. 
 
Figure 2. Generation of HER2 specific mouse CAR T cells: (A) Schematic diagram illustrating the 
modular composition of the retroviral vector encoding HER2 specific CAR. (B,C) Representative flow 
cytometry dot-plots and summary data (HER2 CAR mouse T cells (n = 8) and non-transduced (NT) 
mouse T cells (n = 8)). 
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2.2. HER2 Specific CARs Redirect Mouse T Cells to HER2 Positive Trastuzumab Resistant Tumor Cells 
To demonstrate that the HER2 specific CAR redirects mouse T cells to HER2 positive target cells, 
we co-cultured HER2 CAR T cells with JIMT-1 cells in various effector to target ratios (from 2.5:1 to 
0.01:1). HER2 specific CAR T cells recognized the HER2 positive tumor cells indicated by a significant 
increase in IFNg secretion (p < 0.001). Unmodified (NT) T cells did not induce mIFNg release (Figure 
3A). While HER2 specific CAR induced T cells killed JIMT-1 tumor cells, no killing was observed in 
co-cultures with unmodified T cells (p < 0.001; Figure 3B). Taken together, the HER2 specific CAR 
activates mouse T cells in an antigen-dependent manner and induces antigen-dependent tumor cell 
killing. 
 
Figure 3. In vitro anti-tumor function of HER2 specific mouse CAR T cells: (A) HER2 CAR or non-
transduced (NT) mouse T cells were co-cultured with HER2+ JIMT-1 cells at various (2.5:1–0.01:1) T 
cell to tumor cell ratios. After 48 h, IFNγ release was determined by ELISA (n = 2, assay performed in 
duplicates; HER2 CAR versus non-transduced (NT) T cells: * p < 0.05, *** p < 0.001). (B) XTT-based 
cytotoxicity assay using HER2 CAR T cells or non-modified mouse T cells and HER2 positive JIMT-1 
cells as target at various (2.5:1–0.04:1) T cell to tumor cell ratios (n = 2; assay was performed in 
duplicates; HER2 CAR versus NT T cells: *** p < 0.001). 
2.3. HER2 Specific CAR T Cells Have Antitumor Activity In Vivo against HER2+ Trastuzumab-Resistant 
Tumor Xenografts 
To compare the anti-tumor function of antibody treatment and HER2-redirected CAR T cells, 
we established subcutaneous JIMT-1 xenografts (3 × 106 cells) in SCID mice (day −35, Figure 4). Mice 
were injected with 100 µg trastuzumab intraperitoneally twice weekly from day 0 (35 days after 
tumor cell injection), when average tumor size reached 800 mm3. Control animals were injected with 
PBS (Figure 4) and did not show delayed tumor growth and consequently their overall survival was 
not improved (p = 0.79, Figure 5). These data are in line with our previous observations [13].  
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Figure 4. Outline of in vivo animal treatment schedule: Mice were s.c. injected with 3 × 106 JIMT-1 
cells. 35 days later (on day 0), mice received 100 µL PBS buffer twice weekly (untreated, n = 5), 100 µg 
trastuzumab in 100 µL PBS buffer twice weekly (trastuzumab, n = 5), or an i.v. dose of 2.5 × 105 HER2 
CAR mouse T cells (low-dose HER2 CAR, n = 5), or an i.v. dose of 2.5 × 106 HER2 CAR mouse T cells 
(HER2 CAR, n = 5). Tumor growth was followed by caliper and was derived as the product of the 
length, width and height. 
To evaluate the in vivo efficacy of HER2-CAR T cells against these trastuzumab resistant 
xenografts, 35 days after JIMT-1 inoculation mice were injected iv. with a single dose of 2.5 × 106 
(HER2-CAR T cell group), or 2.5 × 105 (Low Dose HER2-CAR T cell group) congenic mouse T cells, 
7% of them expressing the HER2-CAR. Control mice were treated with 2.5 × 106 unmodified T cells 
(NT T cell group) (Figure 4). In this group, the high number of mouse T cells, in some cases, delayed 
the progression of the human xenografts resulting in better overall survival in comparison to the 
untreated group (Figure 5A–C). In contrast, the same dose of mouse T cells, when transduced with 
the CAR at 7% efficiency, completely eradicated the tumors in 57 days and resulted in long-term 
tumor-free survival. Moreover, complete tumor regression was also observed, by day 105, in the low 
dose HER2-CAR T cell group in which animals received only 250,000 T cells, among them 17,500 CAR 
T cells (Figure 5A–C). There is a cell dose dependence of the rate of tumor regression (p < 0.001). 
Despite the difference in time to complete regression, all CAR T cell treated mice remained tumor 
free until the termination of the experiment (day 150). To assess on-target off-tumor toxicity, 
formaldehyde-fixed paraffin-embedded tissue section weremade from the heart and lungs of each 
sacrificed animal. HE-stained sections were characterized based on morphology by an expert 
histopathologist and showed no signs of mononuclear infiltration (Figure S1A,B). Visual inspection 
upon dissection also did not show signs of inflammation. 
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Figure 5. Antitumor activity of HER2-CAR mouse T cells in a xenograft model: (A) Quantitative 
measurement of tumor volumes (volume = mm3; low dose HER2-CAR versus HER2-CAR groups: *** 
p < 0.001; NT T cell versus HER2-CAR groups *** p < 0.001). (B) Kaplan-Meier survival curve (NT T 
cell versus both HER2 CAR groups *** p < 0.001). (C) Representative images of animals. (D) 
Representative images for the detection of HER2-CAR mouse T cells in JIMT-1 xenografts (field of 
view: 92 µm × 92 µm). HER2-CAR mouse T cells were visualized by AlexaFluor647 conjugated anti-
mouse CD3e and HER2-GFP co-staining. 
To demonstrate that HER2 specific CAR T cells penetrated the JIMT-1 xenografts, tumor samples 
from week 3 after CAR T cell injection were immunostained and analyzed by confocal microscopy. 
We found T cells positive for the CAR and mouse-CD3e confirming the presence of CAR T cells in 
tumor xenografts (Figure 5D). Taken together, we conclude that HER2 specific CAR T cells have 
potent in vivo antitumor activity and penetrate HER2 positive xenografts, which are not eliminated 
by trastuzumab treatment.  
3. Discussion 
In this study, we described the generation of HER2 specific CAR-modified mouse T cells that 
obtained their antigen specificity from trastuzumab, a HER2 specific monoclonal antibody applied 
in clinical practice. We demonstrated that these cells specifically recognize trastuzumab resistant 
HER2 positive JIMT-1 target cells in vitro. Moreover, in vivo a low dose of HER2 CAR T cell expressed 
potent anti-tumor activity in a trastuzumab-resistant mouse xenograft model. 
Although HER2 specific CAR T cells are effective against breast cancer cells [19,22], the tumor 
cells preferentially used as targets were trastuzumab sensitive cell lines (SKBR3 or BT474) leaving the 
question unanswered whether trastuzumab-resistant xenografts can be successfully treated with 
trastuzumab-derived CAR T cells.  
Incorporation of the trastuzumab scFv into the CAR backbone allowed us to compare the 
efficacy in tumor eradication by cytolytic CAR T cells versus antibody mediated cytotoxicity. 
SCID mice exhibit natural killer cell (NK) activity [23], through which trastuzumab treatment 
induces antibody dependent cellular cytotocixity against therapy sensitive xenografts (MCF7; BT-
474) [24], which makes a direct comparison possible. In vivo, we confirmed that trastuzumab 
treatment has no potential to delay or revert the growth of established JIMT-1 tumors. which is in 
line with previous observations [11–14]. 
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Although unmodified mouse T cells in co-cultures with JIMT-1 cells did not release cytokine and 
did not exhibit cytotoxicity, we wanted to confirm that xenogenic immune response does not reject 
human tumor xenografts in vivo [23]. A single injection of 2.5 × 106 unmodified mouse T cells on day 
35 following JIMT-1 implantation could not eradicate the human tumor xenografts; however, in some 
cases, it caused tumor regression and resulted in stable disease.  
In contrast to the control and trastuzumab-treated groups, 2.5 million mouse T cells with a 
proportion of 7% CAR-transduced cells (total ~175,000) caused a complete remission in 57. Even a 
tenth of this dose, 250,000 T cells including ~17,500 CAR T cells, was fully curative, although only in 
105 days. The number of CAR T cells yielding complete remission in the latter case is only 0.2–0.3% 
of the usual 5 to 10 million CAR T cells used in successful mouse CAR-T therapy models [25]. Thus, 
it is likely that this small fraction of specifically redirected T lymphocytes successfully penetrates the 
tumor mass and evokes, in addition to direct tumor killing, a focusing effect that concentrates the 
xenogenic response of non-transduced mouse lymphocytes against the human tumor. By 
extrapolation, it is possible that in the case of HER2 positive solid tumors, a reduced number of CAR 
T cells could still maintain therapeutic efficacy through actively penetrating the tumor and enhancing 
the activity of tumor infiltrating lymphocytes (TILS, [26]). At the same time, while "on target off 
tumor” toxicity (mainly in the cardiopulmonary system), could be avoided owing to the lower 
expression of the HER2 target and the lack of TILs in healthy tissues. 
Overall, we conclude that even a small number of CAR T lymphocytes can evoke a robust anti-
tumor response against an antibody resistant xenograft by focusing the activity of xenogenic T cells. 
This observation may have significance for optimizing the dose of CAR T cells in the therapy of solid 
tumors.  
4. Materials and Methods  
All materials were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise indicated. 
4.1. Cells and Culture Conditions 
HEK 293T packaging cells were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 2 mmol/L Glutamax and 10% Fetal Calf Serum (FCS) and antibiotics. The JIMT-
1 human breast cancer cell line was established in the laboratory of Cancer Biology, University of 
Tampere, Finland [12]. These cells were cultured in 1:1 ratio of Ham’s F-12 and DMEM supplemented 
with 20% FCS, 300 U/L insulin, 2 mmol/L GlutaMAX and antibiotics. Primary mouse splenocytes, T 
cells and CAR T cells were cultured in RPMI 1640 supplemented with 2 mmol/L GlutaMAX, 10% FCS 
and antibiotics. All of the above-listed cells and cell lines were maintained in a humidified 
atmosphere containing 5% CO2 at 37 °C and were routinely checked for the absence of mycoplasma 
contamination. 
4.2. Retrovirus Production and Transduction of T Cells 
Retroviral particles were generated by transient transfection of HEK 293T cells with the MSGV 
retroviral vector containing a trastuzumab derived HER2 specific CAR [17], a Peg-Pam-e plasmid 
containing the sequence for MoMLV gag-pol, and a pMEVSVg plasmid containing the sequence for 
VSVg, using jetPrime transfection reagent (Polyplus, Illkirch, France). Supernatants containing the 
retrovirus were collected after 48 hours (Figure 1A).  
To generate HER2 specific CAR T cells, T cells of syngenic Balb/c mice were isolated from a 
freshly dissected spleen by using a mouse-specific T cell isolation MACS sorting kit (130-095-130; 
Miltenyi Biotech; Bergisch Gladbach, Germany). MACS sorted mouse T cells were plated on non-
tissue culture treated 24-well plates (5 × 106 cells/well), which were pre-coated with 1µg/manti-mouse 
CD3e (ThermoFischer, Waltham, MA, USA) and anti-mouse CD28 (R&D Systems, Min L neapolis, 
MN, USA) antibodies. After 24 h, mouse interleukin 2 (mIL2; 700 U/ml) was added to cultures. T cells 
were then transduced with the previously described retroviral particles on RetroNectin-coated 
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(Takara, Kusatsu, Japan) plates on day 3 in the presence of mIL2 (200 U/m L). The expansion of T 
cells was subsequently supported with mIL2. Anti-mouse CD3e/CD28 activated non-transduced 
(NT) T cells were expanded in parallel with mIL2. Following 48-72h incubation, cells were collected 
and used for further experiments (Figure 1B). 
4.3. Flow Cytometry 
HER2 specific CAR expression was confirmed by a HER2-GFP recombinant protein. T cell purity 
was determined by Alexa Fluor 647 conjugated anti-mouse CD3 antibody (BD Biosciences, San Jose, 
CA, USA) staining. Both molecules were used at 10 µg/mL final concentration for 10 minutes on ice. 
Analysis was performed on at least 10,000 cells per sample using a FACS Calibur (Becton Dickinson, 
Franklin Lakes, NJ, USA) instrument and FCS Express 6 software (De Novo Software, Glendale, CA, 
USA). 
4.4. CAR-Mediated T Cell Activation 
Mouse CAR T cells and non-transduced controls were cultivated in indicator-free RPMI 1640 
medium and 10% (v/v) FCS, without additional stimuli for 24  h, washed and incubated on 96-well 
round-bottomed plates in the presence of JIMT-1 target cells for 48  h. Culture supernatants were 
analyzed for IFN-γ by ELISA (BD Biosciences). IFN-γ was bound to a solid-phase mAb R46A2 and 
detected by a biotinylated mAb XMG1.2. The reaction product was visualized by a peroxidase-
streptavidin conjugate (1:10,000) and ABTS as substrate. To monitor the cytolytic activity, genetically 
modified and control T cells were co-cultured with JIMT-1 target cells with increasing T cell numbers 
for 48 h in 96-well round-bottomed plates. Specific cytotoxicity was monitored by a 2,3-bis[2-
methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide salt (XTT)-based colorimetric 
assay (‘Cell Proliferation Kit II’, Roche Diagnostics, Risch, Switzerland). Reduction of XTT was 
determined as OD at 480 nm for treated tumor cells (Tu), for untreated tumor cells (Max) and for T 
cells only (T). Background (Bg) was measured in complete medium with XTT but no cells. 
Measurements were run with minimally 3 technical replicates in three independent experiments. 
Cytotoxicity was calculated as (1). Cytotoxicity ሺ%ሻ = ቀ1 − ்௨ି்ெ௔௫ି஻௚ቁ ∙ 100%.  (1) 
4.5. Xenograft Tumors and In Vivo Antibody Treatment 
SCID (C.B-17/Icr-Prkdcscid/IcrIcoCrl, Fox-Chase) mice were purchased from Charles River 
Laboratories, and housed in a specific-pathogen-free environment. All animal experiments were 
performed in accordance with FELASA guidelines and recommendations and DIN EN ISO 9001 
standards. Only non-leaky SCID mice with murine IgG levels below 100 ng/mL were used. Each 
seven-week-old female SCID mouse participating in the study was given a subcutaneous injection in 
both flanks, each containing 3 × 106 JIMT-1 cells suspended in 100 µL PBS buffer and mixed with an 
equal volume of Matrigel (BD Biosciences, San Jose, CA, USA). Tumor volumes were derived as the 
product of the length, width and height measured with a caliper.  
The trastuzumab group was treated with 100 µg trastuzumab intraperitoneally in 100 µL PBS 
twice weekly from day 35 post tumor cell injection. The untreated control group was injected with 
100 µl PBS buffer i.p. twice weekly. In the HER2 CAR T cell and unmodified mouse T cell groups 
mice received a single dose of 2.5 × 106 effector cells i.v. on day 35 post JIMT-1 inoculation. In the low 
dose HER2 CAR T cell group mice received 2.5 × 105 cells i.v. (Figure 3A). At the end of the 
experiment, the animals were euthanized. Experiments were approved by the National Ethical 
Committee for Animal Research (# 5-1/2018/DEMÁB).  
4.6. Tumor Xenograft Sections 
At termination, mice were dissected, and fresh tumors were embedded in cryomatrix (Thermo 
Fischer Scientific, Waltham, MA, USA) and snap-frozen in isopentane submerged in liquid nitrogen. 
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Serial 14 µm thick cryosections were made with a Shandon Cryotome (Thermo Fischer Scientific, 
Waltham, MA, USA) at −24 °C and air-dried. Staining was carried out at room temperature and all 
labeling molecules were diluted in PBS buffer supplemented with 1% BSA. After 5 min of rehydration 
in PBS buffer containing 1% BSA and 0.01% TritonX-100 (Thermo Fischer Scientific, Waltham, MA, 
USA) HER2 CAR mouse T cells were stained with HER2-GFP recombinant protein and Alexa Fluor 
647 conjugated anti-mouse CD3e antibodies. Both molecules were used at 2 µg/mL concentration at 
4 °C for 10 hours. Sections were washed three times, for 5, 20, and 60 minutes, fixed in formaldehyde, 
and mounted in Mowiol antifade. 
4.7. Haematoxylin and Eosin Stained Sections 
The heart and lung were resected from sacrificed mice, fixed in 4% paraformaldehyde for 4–6 h, 
dehydrated in ethyl alcohol, and embedded in paraffin. Serial sections of 6 µm were cut with a 
microtome. Deparaffinized sections were HE stained using standard procedures and imaged using a 
Pannoramic digital histopathology scanner with a 20× objective in transmission mode. A trained 
histopathologist has examined the digital slides. 
4.8. Confocal Laser Scanning Microscopy 
Immunofluorescence-labeled tissue sections were analyzed with a confocal laser scanning 
microscope (LSM 510, Carl Zeiss GmbH, Jena, Germany) using a 40× C-Apochromat water immersion 
objective (NA = 1.2). GFP was excited at 488 nm and Alexa Fluor 647 at 633 nm. Corresponding 
fluorescence emissions were separated with an appropriate quad-band dichroic mirror, and detected 
through 505 to 550 nm bandpass and 650 nm longpass filters, respectively. Pinhole was set for 4 µm 
thick optical sections. 
4.9. Statistical Analysis 
GraphPad Prism 5 software (GraphPad software, Inc., La Jolla, CA) was used for statistical 
analysis. Data were presented as mean ± SD or ± SEM. For comparison between two groups, a two-
tailed t-test was used. For comparisons of three or more groups, one-way ANOVA with Bonferroni’s 
post-test was used. For the mouse experiments, survival, determined from the time of tumor cell 
injection, was analyzed by the Kaplan-Meier method and log-rank test. p-values < 0.05 were 
considered statistically significant. 
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CAR Chimeric antigen receptor 
GFP Green fluorescent protein 
HER2 Human epidermal growth factor receptor 2 
IFN-γ Interferon gamma 
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scFv Single Chain Variable Fragment 
SCID Severe combined immunodeficiency 
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